Blanca Ocampo Lim, MD
Internal Medicine · Smyrna, DENPI 1659336782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $918 and has fallen 52.8% since, to $434 in 2025. Among internal medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$786
- AstraZeneca$528
- Sanofi-aventis U.S. LLC$462
- Lilly USA, LLC$434
- Abbott$364
- Amneal Pharmaceuticals LLC$343
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,766100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $786 |
| AstraZeneca | 27 | $528 |
| Sanofi-aventis U.S. LLC | 30 | $462 |
| Lilly USA, LLC | 25 | $434 |
| Abbott | 31 | $364 |
| Amneal Pharmaceuticals LLC | 20 | $343 |
| Merck | 23 | $325 |
| Insulet Corporation | 11 | $318 |
| Xeris Pharmaceuticals, Inc. | 7 | $139 |
| Boehringer Ingelheim | 7 | $138 |
| Amarin Pharma, Inc. | 9 | $127 |
| BD | 3 | $91 |
| Lifescan, Inc. | 4 | $77 |
| Dexcom, Inc. | 4 | $74 |
| Shire North American Group Inc | 4 | $63 |
| GSK | 4 | $58 |
| Corcept Therapeutics | 3 | $50 |
| Seqirus USA Inc | 2 | $38 |
| Cequr Corporation | 2 | $36 |
| Amgen | 2 | $35 |
| Tris Pharma Inc | 2 | $31 |
| AbbVie | 2 | $29 |
| Sanofi US Services Inc. | 1 | $28 |
| Medtronic(2 entities) | 2 | $27 |
| Exact Sciences | 1 | $26 |
| IBSA Pharma Inc. | 2 | $24 |
| Pfizer | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Valeritas, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Mannkind Corporation | 1 | $12 |
How this compares
$4,786 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $200,316 |
| JardianceEmpagliflozin | 125 | $149,860 |
| FarxigaDapagliflozin Propanediol | 96 | $106,762 |
| MounjaroTirzepatide | 72 | $90,841 |
| RybelsusSemaglutide | 38 | $79,417 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $64,677 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $56,120 |
| JanuviaSitagliptin Phosphate | 40 | $47,287 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $40,897 |
| TradjentaLinagliptin | 35 | $39,643 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $29,312 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $24,961 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $22,268 |
| VascepaIcosapent Ethyl | 21 | $17,685 |
| TrulicityDulaglutide | 16 | $14,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $786 | $279,733153 claims |
| Boehringer IngelheimJardiance, Tradjenta | $138 | $189,502160 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin N | $434 | $108,104100 claims |
| AstraZenecaFarxiga | $528 | $106,76296 claims |
| MerckJanuvia, Janumet | $325 | $60,94054 claims |
| AbbVieSynthroid, Armour Thyroid | $29 | $5,49691 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $343 | $4,848459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Smyrna
- Islam Al JunaidiSmyrna$10K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
- Fadi DamouniMillsboro$17K
- Rene BadilloBear$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.